YTHDF1 promotes pancreatic cancer cell progression by enhancing SF3B2 translation though m6A modification
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.N6-Methyladenosine (m6A) binding protein YTHDF1 promotes pancreatic cancer growth and invasion. It enhances splicing factor SF3B2 translation, offering a potential therapeutic target for pancreatic cancer.
Area Of Science
- Molecular Biology
- Cancer Research
- Epigenetics
Background
- N6-Methyladenosine (m6A) is a key RNA modification involved in various cancers.
- YT521-B homology domain family protein 1 (YTHDF1) binds m6A and influences target translation.
- The role of YTHDF1 in pancreatic cancer remains largely unknown.
Purpose Of The Study
- To investigate the role and mechanism of YTHDF1 in pancreatic cancer progression.
- To explore YTHDF1's interaction with downstream targets in pancreatic cancer cells.
Main Methods
- Quantitative analysis of YTHDF1 expression in pancreatic cancer cell lines.
- Functional assays (knockdown and overexpression) to assess YTHDF1's impact on cell proliferation and invasion.
- Co-immunoprecipitation to identify YTHDF1 interacting partners.
- Western blotting and qRT-PCR to analyze protein and mRNA levels of SF3B2.
Main Results
- YTHDF1 was significantly upregulated in pancreatic cancer cell lines (SW1990, PANC-1) compared to normal cells.
- YTHDF1 knockdown inhibited, while overexpression promoted, pancreatic cancer cell proliferation and invasion.
- YTHDF1 directly interacted with the SF3B2 coding sequence.
- YTHDF1 downregulation reduced SF3B2 protein levels post-transcriptionally.
- SF3B2 overexpression rescued the inhibitory effects of YTHDF1 knockdown on cell proliferation and invasion.
Conclusions
- YTHDF1 promotes pancreatic cancer progression by enhancing SF3B2 translation via m6A modification.
- YTHDF1 represents a potential therapeutic target for pancreatic cancer.
- This study provides new mechanistic insights into pancreatic cancer development.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...